Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
145.66
-3.81 (-2.55%)
At close: May 15, 2026, 4:00 PM EDT
145.98
+0.32 (0.22%)
After-hours: May 15, 2026, 7:59 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
30.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
RVMD News
- 3 days ago - US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters
- 10 days ago - Revolution Medicines price target raised to $185 from $170 at BofA - TheFly
- 10 days ago - Revolution Medicines price target raised to $172 from $120 at Piper Sandler - TheFly
- 10 days ago - Revolution Medicines price target raised to $205 from $175 at Guggenheim - TheFly
- 11 days ago - Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84) - TheFly
- 11 days ago - Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B - TheFly
- 11 days ago - Revolution Medicines announces NEJM publication of data on Daraxonrasib - TheFly
- 11 days ago - Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer - GlobeNewsWire